eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation
Small · 2026
DOI: 10.1002/smll.202508128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2026. Verfasst von Manju Shrestha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Inflammation, CRISPR-Associated Protein 9, CRISPR-Cas Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Korean government, Ministry of Health and Welfare.
Abstract (Originalsprache)
Islet transplantation is a promising strategy for effective β‐cell replacement in patients with type 1 diabetes. However, its success is hindered significantly by instant blood‐mediated inflammatory reaction (IBMIR), which leads to rapid graft loss. IBMIR is triggered when the transplanted islets come in contact with blood, activating the coagulation cascade, complement pathways, and innate immune responses. Tissue factor (TF), abundantly expressed on the islet surface, initiates the coagulation cascade, leading to thrombin formation, platelet activation, and neutrophil infiltration. Plasminogen activator inhibitor‐1 (PAI‐1) plays a critical role in IBMIR by inhibiting fibrinolysis and causing ischemic injury in the graft. TF and PAI‐1 contribute significantly to IBMIR, thus making them critical targets for genetic interventions to prevent IBMIR. In this study, an engineered virus‐like particle (eVLP)–mediated Cas9 nuclease is employed to knock out TF and PAI‐1 genes in rat islets. TF and PAI‐1 expression are effectively downregulated without inducing any off‐target effects or without compromising the viability and functionality of the islets. Streptozotocin‐induced diabetic mice transplanted with TF ‐ and PAI‐1 ‐knockout islets exhibited improved glycemic control and a significant reduction in the plasma levels of thrombin‐antithrombin (TAT) complex and complement component 3a (C3a), indicating the successful inhibition of IBMIR post‐transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
- Research Institute for Convergence Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
- Department of Metabiohealth, Institute for Cross-disciplinary Studies, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing, 210009, China.
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, 210009, China.
ORCID-Profile: Manju Shrestha, Jee-Heon Jeong
Förderung
- National Research Foundation of Korea
- Korean government
- Ministry of Health and Welfare
- Ministry of Science and ICT, South Korea
Zitieren
APA
Shrestha, M., Kim, Y., Park, S., Jiang, H. L., Lee, J. Y., Kim, D., & Jeong, J. H. (2026). eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation. Small. https://doi.org/10.1002/smll.202508128
Vancouver
Shrestha M, Kim Y, Park S, Jiang HL, Lee JY, Kim D, et al. eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation. Small. 2026. doi:10.1002/smll.202508128
BibTeX
@article{Shrestha2026,
author = {Shrestha, Manju and Kim, Yeonji and Park, Subin and Jiang, Hu-Lin and Lee, Jae-Young and Kim, Daesik and Jeong, Jee-Heon},
title = {eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation},
journal = {Small},
year = {2026},
doi = {10.1002/smll.202508128}
}
EUVIMED